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Abstract: Aims: There is limited data on health-related quality of life (HRQoL) in locally advanced
rectal cancer. We assessed HRQoL before, during and after neoadjuvant chemoradiation, correlated
this to corresponding clinician-reported adverse events (CR-AEs) and explored disparities between
patients of Asian ethnicity versus Caucasians. Correlation between HRQoL and treatment response
was also assessed. Methods: A consecutive sample of patients was recruited. HRQoL was assessed
with the EORTC QLQ-C30 before chemoradiation, week three of chemoradiation and one-week
pre-surgery. Clinical variables including CR-AEs were recorded at these time-points. Patients
self-reported socio-demographic variables. Treatment response was assessed by the tumour regression
grade. HRQoL data were analysed with multilevel models. Results: Fifty-one patients were recruited.
HRQoL completion rates were ≥86%. Cognitive and role functioning worsened significantly during
treatment. Emotional, role and social functioning improved significantly at pre-surgery. Fatigue and
nausea/vomiting worsened during treatment while fatigue, appetite loss, diarrhoea and financial
difficulties improved from treatment to pre-surgery. Almost 30% of the cohort were Asian ethnicity.
Differences were found in multiple HRQoL domains between Asians and Caucasians, with Asians
faring worse. Significant differences were evident in physical, role and cognitive functioning, and
in seven out of the 8 symptom scales. The correlation between patient-reported outcomes and
clinician-reported outcomes was weak, with diarrhoea having the strongest correlation (r = 0.58).
Vomiting during treatment correlated with poor response, whilst baseline constipation correlated
with good response. Conclusion: Chemoradiation for locally advanced rectal cancer affects multiple
HRQoL domains. Our findings highlight the importance of psychological aspects of treatment.
Significant differences were identified between the Asian and Caucasian populations, with Asians
consistently performing worse. Poor correlations between patient and clinician reporting strongly
support the inclusion of patient-reported outcomes in clinical studies. HRQoL domains of vomiting
and constipation are potential biomarkers of treatment response.
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1. Introduction
Colorectal cancer is the second most common cancer in females and third most common in males [1].
Rectal cancers comprise a third of colorectal cases. Of these, a third are locally advanced rectal cancer
(LARC) which carry a poorer prognosis [2]. LARC is treated with trimodality therapy consisting
of neoadjuvant radiation and chemotherapy, surgery and adjuvant chemotherapy [3]. Radiation is
administered over 5–6 weeks with radiosensitising 5-fluorouracil or capecitabine. Following surgery,
patients receive adjuvant chemotherapy. Despite trimodality therapy, recurrence rates are around 40%.
The quality of survivorship during and following trimodality treatment is an important issue.
Although health-related quality of life (HRQoL) is central to treatment goals, there is limited data.
The few studies on LARC, which utilize the EORTC QLQ-C30 and QLQ-CR38, are summarised below.
HRQoL was assessed before and after neoadjuvant chemoradiation, then 6- and 12-month
post-surgery (n = 149) [4]. Physical, social functioning and body image decreased, while fatigue
increased after treatment and normalised at 12 months. Global health status remained stable.
There was a trend toward improvement in emotional functioning. Radiation-related toxicities of sexual
dysfunction, faecal incontinence and impairment in bowel function were present at 12 months.
In another study (n = 42), 26 had neoadjuvant radiotherapy while 16 had post-operative
radiotherapy [5]. HRQoL was assessed at the start and end of radiotherapy, and 4–6 weeks later.
At the end of treatment, diarrhoea, fatigue and appetite loss significantly improved compared to
pre-radiotherapy. There were small decreases in physical function and body image at the end of
radiotherapy. All scores returned to baseline at 4–6 weeks.
Long-term HRQoL outcomes were assessed at 43 months post-neoadjuvant chemoradiation and
radical surgery (n = 101), relative to the general population. Global health status, physical, role, social,
emotional and cognitive functioning were not significantly different [6]. Social functioning was poorer;
and constipation and diarrhoea were more prevalent. Interestingly, patients reported less pain, perhaps
due to “response shift”, an adaptive psychological response [7].
Only one study (n = 50) assessed HRQoL outcomes during neoadjuvant chemoradiation, in a
largely Caucasian population [8]. Nausea, vomiting, fatigue, dyspnoea, diarrhoea and urinary
problems increased during treatment but returned to baseline levels post-treatment. Financial
difficulties remained elevated. While completion rates for sexual function were poor, available data
suggested it remained diminished post-treatment. Physical, role and global QoL decreased during
chemoradiation and returned to baseline levels 4–6 weeks post-treatment. The authors noted that
physician-rated toxicities may not capture patients’ experiences as fully as patient-reported outcomes.
Thus, neoadjuvant chemoradiation carries significant morbidity that may be under-recognised.
Studies have focused on acute radiation-specific toxicities in a before-and-after design. Only one study
investigated the impact on HRQoL during the treatment phase, when intervention may be possible.
Potential under-reporting by physicians of toxicities may justify the inclusion of patient-reported
HRQoL [9]. Further, physical toxicities are often the focus, while psychological impacts such as
anxiety and depression are often neglected. There is also little literature on ethnic variability, and
even less on South-East Asian, Middle-Eastern and South Asian populations. Available studies are in
African–American and Japanese–American populations [10]. Given recognised cultural differences in
perceptions of health care and symptom reporting, potential racial disparities may exist [11].
Tumour response to neoadjuvant therapy in LARC is measured by the tumour regression grade
(TRG) scored on the surgical histopathological specimen. TRG has been shown to be prognostic for
survival [12]. No studies have explored the correlation of HRQoL to TRG in LARC, although studies
in metastatic colorectal cancer have correlated HRQoL to survival [13–16].
Our aims in this study were to address these deficiencies in the literature:
(1) Assess HRQoL before, during and after neoadjuvant chemoradiation.
(2) Assess the association between patient-reported HRQoL domains and corresponding clinician- reported
adverse events (CR-AEs) and Eastern Cooperative Oncology Group (ECOG) performance status.
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(3) To assess disparities between the Asian and Caucasian population.
(4) To assess whether HRQoL domain scores differ by tumour response as measured by the TRG.
2. Methods
Ethics approval was obtained from the Sydney South-West Area Health Service Ethics Committee
(HREC/13/LPPL/158). Patients were prospectively recruited from Liverpool, Bankstown and Campbelltown
Hospitals, Australia from 2014–2016.
The inclusion criteria were: age > 18; tissue confirmation of rectal adenocarcinoma stage T3/T4 or
node positive disease; no evidence of metastatic disease on computed tomography (CT) imaging of
chest/abdomen/pelvis; treated with neoadjuvant chemoradiation. The treatment algorithm consisted
of neoadjuvant chemotherapy with infusional 5-fluorouracil therapy or oral capecitabine concurrent
with radiotherapy for 5–6 weeks, followed by surgery approximately 6–12 weeks post-treatment.
Data were collected within one week of commencing neoadjuvant chemoradiation (baseline),
week three of treatment and post-treatment at one week before surgery.
HRQoL was assessed with the EORTC QLQ-C30, a validated measure of core aspects of HRQoL
and symptoms commonly experienced by cancer patients [17,18]. Standard scoring was used, yielding
nine multi-item scales and six single-item scales [19]. For multi-item scales, the scale score was the
average of the non-missing component items, as long as half or more items within the scale were
completed; if more than half the items were missing, the scale was set to missing. Raw scores were
linearly transformed to obtain scores ranging 0–100. On the functioning and global health status/QoL
scales, a higher score indicated a better outcome, while on the symptom scales, a higher score indicated
a worse outcome.
Side effects of chemoradiation were recorded by physicians at these same time-points, graded
using the Common Toxicity Criteria for Adverse Events (CTC-AE) version 4.0 [20], and included
symptoms commonly experienced during chemoradiotherapy: diarrhoea, pain, fatigue, weight loss,
nausea, vomiting, constipation, anorexia, insomnia and depression.
ECOG performance status [21] and demographic data were also recorded. The Indian
sub-continental population (South Asian), East Asian, South-east Asian, Middle-Eastern and Polynesian
patients were classified as Asian in our analysis. The Australian, New Zealander, North American and
European population were classified as Caucasian.
TRG was scored by two specialist pathologists on the surgical specimens. Embedding the whole
of the surgical tissue representing the original site of tumour was mandatory. All discrepancies
between pathologists were resolved through consensus. The system used was that recommended by
the American Joint Committee on Cancer (AJCC) using a four-point scale adapted from Ryan et al.
with zero being complete tumour response with no viable tumour cells, and three being poor response
with extensive residual tumour [2]. TRG 0–1 were classed as good responders and TRG 2–3 were
classed as poor responders.
3. Statistical Methods
For each HRQoL outcome, multilevel models were used to compare HRQoL over the three
time-points, and pairwise comparisons were then used to analyse differences between the time-points.
Additionally, multilevel models using time-point, ethnicity and interaction between ethnicity and
time-point as predictors were used to compare differences in outcomes between Asians and Caucasians
at each time-point. This small study was descriptive and hypothesis-generating, and we used a p-value
of 0.05 to highlight results of potential significance. We also used QLQ-C30 interpretation guidelines to
assess clinical significance [22].
The association between patient-reported symptoms and corresponding clinician CTC-AE and
ECOG performance status was assessed with Spearman’s correlation coefficient. Because in each case,
patients and clinicians were assessing the same symptom, we considered correlations r ≥ 0.70 to be
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strong, r = 0.40–0.69 to be moderate, and r = 0.10–0.39 to be weak [23]. Boxplots were used to assess
the range of patient-reported symptoms in each AE category.
Multilevel models using time-point, TRG and interaction between TRG and time-point as




Fifty-one patients were prospectively recruited. Completion rates for HRQoL questionnaires were
84% at baseline (43/51), 88% at week 3 (45/51) and 86% (38/44 still on study) pre-surgery. Reasons
for coming off study included disease progression, withdrawal from study and patient refusal to
undergo surgery. Lack of completion was generally due to an English language barrier and missed
appointments. Toxicity data was recorded in 94% (48/51) of patients at baseline, 98% (50/51) at week
three and 93% (41/44) pre-surgery. Table 1 summarises the patient characteristics.
Table 1. Demographics and clinical profile of patient sample at baseline (n = 51).































































4.2. Health-Related Quality of Life Domains and Symptom Scales of Study Population
Fatigue and nausea/vomiting increased significantly during treatment (p = 0.015 and p = 0.026
respectively). Symptoms of fatigue, appetite loss, diarrhoea and financial difficulties improved from
treatment to pre-surgery (p = 0.001, p = 0.035, p = 0.0026 and p = 0.018 respectively). Cognitive and
role function worsened significantly during treatment (p = 0.043 and p = 0.02 respectively). The latter
improved significantly from treatment to pre-surgery (p = 0.03). Emotional functioning improved
significantly from baseline to pre-surgery (p = 0.049). Social functioning worsened during treatment
but improved significantly from both baseline and treatment levels to pre-surgery (p = 0.0078 and
p = 0.019 respectively). All these changes were clinically important (Table S1) [22].
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Figure 1 graphs the means and confidence intervals at the three time-points of each HRQoL
domain. Table S1 in the Supplementary Material lists the means, confidence intervals, p-values and
clinical significance of all pair-wise comparisons for all the HRQoL domains.
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4.3. Health-Related Quality of Life Domains and Symptom Scales in Asian and Caucasian Populations
Differences were found in almost all the HRQoL domains between Asians and Caucasians,
with Asians faring significantly worse. The bar graphs in Figure 2 show the mean scores between
the two groups and the significant pair-wise comparisons (all of which were clinically significant).
Means and confidence intervals for each domain and ethnic group are reported in Table S2 in the
Supplementary Material, along with p-values and clinical significance of all pair-wise comparisons.
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For functional scales, the Caucasian group on average had higher scores at baseline and a marked
improvement pre-surgery while the Asian group had consistently lower scores and did not improve
pre-surgery. Statistically and clinically significant pair-wise comparisons were evident in physical
functioning at pre-surgery, role functioning at week three and in cognitive function at week three
and pre-surgery.
Seven of the eight symptom scales showed statistically and clinically significant differences
between Asians and Caucasians; in each case Asians reported higher levels of symptoms. Fatigue was
worse in Asians at all three time-points. Pain was worse at baseline and during treatment in Asians.
Dyspnoea was worse during treatment in Asians, and financial difficulties were greater. Constipation
was also worse during treatment and at pre-surgery. Nausea and vomiting, as well as diarrhoea were
worse in Asian patients at pre-surgery.
4.4. Adverse Events and Correlation between Patient-Reported Outcomes and Clinician-Reported Outcomes
Adverse events and ECOG performance status are shown in Table 2, most adverse events being
grade 1. There were no grade 4 toxicities, nor ECOG level 4.
Table 2. Adverse events as graded by Common Toxicity Criteria (CTC-AE) and Eastern Cooperative
Oncology Group (ECOG) performance status at week three of chemoradiation, n = 50.
CTC-AE Specific Toxicity or ECOG * Grade 0 Grade 1 Grade 2 Grade 3
Diarrhoea (%) 76 18 4 2
Pain (%) 90 8 2 0
Fatigue (%) 40 60 0 0
Weight loss (%) 94 6 0 0
Nausea (%) 76 22 2 0
Vomiting (%) 96 4 0 0
Constipation (%) 90 10 0 0
Anorexia (%) 88 10 2 0
Insomnia (%) 94 6 0 0
Depression (%) 92 8 0 0
ECOG performance status (%) 56 44 0 0
* no patients experienced grade 4 for any CTC-AE toxicity or were graded as ECOG = 4.
Diarrhoea and nausea displayed relatively strong correlations between patient-reported symptoms
and CTC-AE, while fatigue, anorexia, pain and depression were moderately correlated. Insomnia had
a very poor correlation (Table 3). Table 3 also shows mean patient-reported outcomes for patients rated
by clinician as not having adverse events versus those having any grade of adverse event. Figure 3
illustrates the box and whisker plots of patient-reported outcomes plotted against clinician-reported
adverse events. This highlights the extent of possible disagreement between patients and clinicians
in reporting symptoms. For example, while diarrhoea had the strongest correlation (r = 0.58) and a
clear difference in mean patient-reported scores between CTC-AE grade 0 versus grade 1 or more,
some patients assigned grade 0 reported quite high levels of diarrhoea while some graded 1 or more
reported no diarrhoea. These discrepancies were more common for all other domains, as these all had
lower correlation.
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Table 3. Association between patient-reported outcomes and corresponding clinician-reported adverse







Mean (SD) PRO for
Patients with CTC AE
Toxicity Grade 0 †
Mean (SD) PRO for
Patients with CTC AE
Toxicity Grade ≥ 1 †
Diarrhoea Diarrhoea 0.58 13.7 (18.6) 54.6 (30.8)
Nausea Nausea 0.54 12.1 (23.3) 50.0 (36.2)
Fatigue Fatigue 0.44 24.2 (25.5) 45.2 (24.9)
Anorexia Appetite loss 0.35 18.3 (26.1) 60.0 (43.5)
Depression Depression 0.32 21.4 (26.4) 55.6 (19.2)
Pain Pain 0.31 21.5 (26.2) 58.3 (39.7)
Constipation Constipation 0.24 12.5 (18.0) 40.0 (43.5)
Insomnia Insomnia 0.06 31.8 (31.7) 50.0 (70.7)
† Patient-reported outcome item or multi-item scale that most closely corresponds to the clinician-reported outcome.
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5. Discussion
We found chemoradiation for LARC affected multiple HRQoL domains. Cognitive and role
functioning deteriorated with treatment, emotional functioning improved from baseline to pre-surgery,
while role functioning improved from treatment to pre-surgery. Not much is known about cognitive
function during neoadjuvant chemoradiation, although impairment in cognition is a well-recognised
side effect of chemotherapy and long-term symptom in colorectal cancer survivors [24]. The trend
in role function is consistent with findings by Herman et al. [8]. Pucciarelli et al. also shows a trend
toward an improvement in emotional functioning, though this was at many months post-treatment [4].
This may be explained by an adjustment to cancer diagnosis, improvement in physical symptoms and
psychological adaptation.
Social functioning scores decreased during chemoradiation, but improved significantly from both
baseline and treatment levels to pre-surgery. These findings are consistent with the literature, which
has reported a fall in social functioning during or immediately post-treatment, then normalisation
of these scor s post-treatment [4,5,8]. However, these studies reported post-treatment scores ei her
at 4–6 weeks, when radi tion toxicities would hav receded, r many months post-treatment hen
adjuvant ch mother py is completed and stoma reversed. Timing of surgery was not specified.
We have r ported scores 6–12 weeks post-treatment, which is an important milestone in the treatment
course before surgery.
We found that global health status remained unchanged. Herman et al. [8] reports a fall in global
health scores but these normalised 4–6 weeks post-treatment. All remaining studies similarly reported
no significant changes [4,5]. Consistent with the literature [4,5,8], our reported symptoms of fatigue,
appetite loss and diarrhoea significantly increased during neoadjuvant treatment.
There were marked differences identified at various time-points between the Asian and Caucasian
populations, with Asians consistently faring worse with poorer function and more symptoms.
The reasons for poorer HRQoL in Asians during and after treatment could be due to cultural differences
in symptom reporting, perceptions of the health system, adherence to Western medicines, knowledge
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and compliance [10]. There are also reported inter-ethnic differences in metabolism, however no
differences were found in drug pharmacokinetics between Caucasians and Japanese [11,25,26]. There
is also no data to suggest that Asians have worse biology, though they may present later, reflecting
socio-demographical differences [27]. However, we note that the disease-related symptoms of diarrhoea
and constipation are not worse in our Asian cohort at presentation.
Most previous studies have focused on effects of chemotherapy, while some included patients with
rectal cancer undergoing multimodal therapy [28]. A core set of symptoms identified include nausea,
fatigue, pain, depression and dyspnoea. We included these in our clinician assessment. Adverse events
in our study were mostly grade 1. There was a 2% rate of grade 3 diarrhoea and no grade 4 toxicities.
These clinician-reported toxicity data were consistent or slightly lower than reported [8].
We found a range of correlations between clinician-reported and patient-reported outcomes.
Diarrhoea had the strongest correlation with a coefficient of 0.58. Even so, some patients assigned grade
0 reported high levels of diarrhoea while some graded ≥1 reported no diarrhoea. These discrepancies
were more common in all other symptoms with poorer correlations. Insomnia has a particularly poor
correlation (r = 0.06). These findings are consistent with the literature in other tumour types [29].
A retrospective subgroup study (n = 65) looking at patient and clinician-reported outcomes during
chemoradiation in LARC reported on concordance between incidence of symptoms and found a
correlation of 0.64 for diarrhoea [30].
Our findings strongly support the inclusion of patient-reported outcomes in clinical studies as
under-recognition of patient symptoms by clinicians reduces the potential for intervention. Routine
assessment of patient-reported outcomes can achieve clinical benefits when used to inform patient
care, as shown in a randomised controlled study of outpatients undergoing chemotherapy [31,32].
To our knowledge, this is the first study that has attempted to correlate HRQoL and tumour
response, which is prognostic of survival in LARC. Studies in metastatic colorectal cancer indicate
that HRQoL are predictive of survival. We found that worse vomiting on treatment correlated to poor
response. The presence of constipation at baseline predicted for a good response. We hypothesise
that worse vomiting may result in decreased tolerability and absorption of systemic radiosensitising
therapy, or may be related to the tumour cytokine milieu. Constipation at baseline may be a reflection
of a responsive type of symptomatic tumour burden.
While small sample size is a limitation, features of our study that add to the scant available evidence
include reporting of serial measurements, selecting key clinically relevant time-points, comparison of
clinician and patient-reported symptoms including psychological aspects of treatment. Importantly,
we explored potential ethnic differences. We have also shown several HRQoL domains to correlate
with tumour response, supporting increasing literature in the metastatic setting that demonstrate
HRQoL to predict for survival. However, we acknowledge that not including the EORTC QLQ-CR38
will likely miss some important symptoms.
6. Conclusions
Our study provides much needed information about the symptom experience of patients with
LARC, about which relatively little is known yet it is increasingly recognised as being key to
patient-centred care. Poor correlations were found between patient and clinician reporting, which
strongly support the inclusion of patient-reported outcomes in clinical studies. Importantly, we have
shown marked ethnic disparities, which deserve further exploration in a larger study, and consideration
of their causes and implications. Further exploration of HRQoL with tumour response with larger
patient numbers, and correlating with long-term endpoints of survival, will be of clinical benefit.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1263/s1,
Table S1: Health-related quality of life domains and symptom scales at baseline, week three of chemoradiation
and pre-surgery, Table S2: Health-related quality of life domains and symptom scales at baseline, week three of
chemoradiation and pre-surgery in Asian and Caucasian groups, Table S3: Health-related quality of life domains
and symptom scales at baseline, week three of chemoradiation and pre-surgery in good and poor responders.
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